REPLIGEN CORP Increase (Decrease) in Other Operating Assets
REPLIGEN CORP (RGEN) reported Increase (Decrease) in Other Operating Assets of -$471.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2025-03-14
- REPLIGEN CORP increase (decrease) in other operating assets for the quarter ending 2024-06-30 was -$44.00K, a 109.69% decline year-over-year.
- REPLIGEN CORP increase (decrease) in other operating assets for the quarter ending 2024-03-31 was -$320.00K, a 173.73% decline year-over-year.
- REPLIGEN CORP increase (decrease) in other operating assets for the quarter ending 2023-12-31 was -$246.00K.
- REPLIGEN CORP increase (decrease) in other operating assets for the quarter ending 2023-09-30 was -$181.00K.
- REPLIGEN CORP increase (decrease) in other operating assets for fiscal 2024 was -$471.00K, a 202.17% decline from fiscal 2023.
- REPLIGEN CORP increase (decrease) in other operating assets for fiscal 2023 was $461.00K, a 99.57% increase from fiscal 2022.
- REPLIGEN CORP increase (decrease) in other operating assets for fiscal 2022 was $231.00K.
- REPLIGEN CORP increase (decrease) in other operating assets for fiscal 2021 was -$430.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 3 month as first filed | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 9 month as first filed | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$471.00K 10-K · filed 2025-03-14 | ||||||
| 2024-06-30 | -$44.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$364.00K 10-Q/A · filed 2024-11-18 | -$610.00K derived: sum of 3 quarters · filed 2025-03-14 | -$791.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2024-03-31 | -$320.00K 10-Q/A · filed 2024-11-18 | -$566.00K derived: sum of 2 quarters · filed 2025-03-14 | -$747.00K derived: sum of 3 quarters · filed 2025-03-14 | -$293.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-12-31 | -$246.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | -$427.00K derived: sum of 2 quarters · filed 2025-03-14 | $27.00K derived: sum of 3 quarters · filed 2025-03-14 | $461.00K 10-K · filed 2025-03-14 | |||
| 2023-09-30 | -$181.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $273.00K derived: sum of 2 quarters · filed 2024-11-18 | $707.00K 10-Q/A · filed 2024-11-18 | $640.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-06-30 | $454.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $888.00K 10-Q/A · filed 2024-11-18 | $821.00K derived: sum of 3 quarters · filed 2025-03-14 | $713.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-03-31 | $434.00K 10-Q/A · filed 2024-11-18 | $367.00K derived: sum of 2 quarters · filed 2025-03-14 | $259.00K derived: sum of 3 quarters · filed 2025-03-14 | $461.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2022-12-31 | -$67.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | -$175.00K derived: sum of 2 quarters · filed 2025-03-14 | $27.00K derived: sum of 3 quarters · filed 2025-03-14 | $231.00K 10-K · filed 2025-03-14 | |||
| 2022-09-30 | -$108.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $94.00K derived: sum of 2 quarters · filed 2024-11-18 | $298.00K 10-Q/A · filed 2024-11-18 | $596.00K derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2022-06-30 | $202.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $406.00K 10-Q/A · filed 2024-11-18 | $704.00K derived: sum of 3 quarters · filed 2024-11-18 | $1.72M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2022-03-31 | $204.00K 10-Q/A · filed 2024-11-18 | -$1.31M 10-Q · filed 2022-04-27 | $502.00K derived: sum of 2 quarters · filed 2024-11-18 | $1.52M derived: sum of 3 quarters · filed 2024-11-18 | $312.00K derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2021-12-31 | $298.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $1.32M derived: sum of 2 quarters · filed 2024-11-18 | $108.00K derived: sum of 3 quarters · filed 2024-11-18 | -$430.00K 10-K/A · filed 2024-11-18 | -$432.00K 10-K · filed 2022-02-17 | ||
| 2021-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$190.00K derived: sum of 2 quarters · filed 2022-11-01 | -$728.00K 10-Q · filed 2022-11-01 | -$751.00K 10-Q · filed 2021-10-28 | -$1.16M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$1.75M 10-Q · filed 2022-08-02 | -$2.18M derived: sum of 3 quarters · filed 2023-02-22 | -$2.00M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-03-31 | -$538.00K 10-Q · filed 2022-04-27 | -$753.00K 10-Q · filed 2021-05-04 | -$973.00K derived: sum of 2 quarters · filed 2023-02-22 | -$789.00K derived: sum of 3 quarters · filed 2023-02-22 | |||
| 2020-12-31 | -$435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$251.00K derived: sum of 2 quarters · filed 2023-02-22 | -$175.00K 10-K · filed 2023-02-22 | $281.00K 10-K · filed 2022-02-17 | |||
| 2020-09-30 | $184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $260.00K 10-Q · filed 2021-10-28 | |||||
| 2020-06-30 | $76.00K 10-Q · filed 2021-07-27 | ||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $1.00K derived: sum of 2 quarters · filed 2022-02-17 | $66.00K 10-K · filed 2022-02-17 | ||||
| 2019-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $66.00K 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $65.00K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |